Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9283209 | NOVARTIS PHARMS CORP | Oral formulations of deferasirox |
Nov, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
M | Jul 23, 2023 |
Market Authorisation Date: 30 March, 2015
Treatment: NA
Dosage: TABLET;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic